SEC Form 4 · accession 0001104659-18-058771
IMMUNOMEDICS INC · IMMU
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jared Freedberg
Officer — GENERAL COUNSEL
Period of report
Sep 24, 2018
Accepted (ET)
Sep 26, 2018 · 5:00 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000722830
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $21.72 | Sep 24, 2018 | A | 119,685 | A | Sep 24, 2019 | Sep 24, 2025 | Common Stock, par value $0.01 per share | 119,685 | 119,685 | D |
Explanation of responses
- F1The reporting person was granted stock options pursuant to the Company's 2014 Long-Term Incentive Plan. The stock options vest 25% on the first anniversary of the date of grant and 2.08333% on a monthly basis thereafter.